Targeted cancer drugs scrutinized in Canadian study; Merck Serono fails to make deal with Geneva workers;

NEW! Conversations on  Twitter :

 @FierceBiotech: New compound nearly wipes out HIV in cells. More | Release | Follow @FierceBiotech

 @JohnCFierce: Sanofi/Regeneron enrolling 22,000 patients for Phase III PCSK9 program. Let the LDL games begin. Release | Follow @JohnCFierce

 @RyanMFierce: CHMP has backed approval of gene therapy for 1st time. How big of a 'first' is this in biotech business? Release | Follow @RyanMFierce

> Canadian researchers scrutinized the potential for higher risks of certain side effects from new cancer drugs. Article

> The EMA accepted Pfizer's application for approval of bazedoxifene/conjugated estrogens from partner Ligand Pharmaceuticals ($LGND) for treating estrogen deficiency and osteoporosis in certain women. Item

> Canada-based Nuvo Research says that it expects to collect $6 million in milestone fees from partner Galderma related to Galderma's license to Pliaglis. Release

> Merck Serono failed to satisfy unhappy union members in negotiations about severance to workers affected by the closure of its headquarters in Geneva, Switzerland. News

Pharma News

 @FiercePharma: Pfizer foils genericsmakers on Lyrica for 5 years. Last year's sales? $3.7B. Report | Follow @FiercePharma

 @EricPFierce: WSJ: J&J, feds reach deal of up to $2.2 billion; J&J to pay $400 million fine but keep selling to federal programs. Story | Follow @EricPFierce

> Did anemia drug giants game the system to rake in billions? Article

> Nacto may next attack Pfizer, Roche drugs with compulsory license. News

> Some docs not so hot on potential for diet drugs Qsymia, Belviq. More

> Pfizer foils genericsmakers on Lyrica for 5 years. Story

Medical Device News

@FierceMedDev: Roche Diagnostics plans to roll out a new interactive insulin pump system later this year. Article | Follow @FierceMedDev

 @MarkHFierce: What were the top 10 VC medical device deals in H1 2012? Report | Follow @MarkHFierce

> Second Sight to argue for FDA approval of retinal prosthesis. Story

> Study: FDA device recall databases don't collect hacking data. Article

> Kips Bay Medical pursues new IDE for artery graft mesh device. More

> Med device VC deals are rising but the dollar volume remains flat. Report

And Finally… Bloomberg spotlighted Merck's ($MRK) sleeping pill in late-stage development. Item

Suggested Articles

Loretta Itri, M.D. has been helping Immunomedics out with its troubled antibody-drug conjugate. Now, she’s signing on as its chief medical officer.

Light Chain Bioscience, a unit of Swiss biotech Novimmune, has been handed a nice royalty milestone check from partner Takeda.

The fund received money from Chinese organizations inside and outside the biopharma industry, enabling CICC Capital to ease past its financing goal.